15 March 2024
TruSpine Technologies plc
("TruSpine" or the "Company")
Result of Adjourned AGM
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that at the Company's 2022 adjourned annual general meeting ("2022 AGM") held earlier today, the resolution was duly passed.
Enquiries:
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
Laurence Strauss, Chief Executive Officer |
|
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti |
|
Peterhouse Capital Limited (Broker & Financial Adviser) |
|
Lucy Williams / Duncan Vasey
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)207 448 9839 |
Alan Green / Jacqueline Briscoe |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.